Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice

Journal of Orthopaedic Research

Volumn 26, Issue 1, 2008, Pages 65-74

  Schindeler, Aaron ^a,b   Ramachandran, Manoj ^a   Godfrey, Craig ^a   Morse, Alyson ^a   McDonald, Michelle ^a   Mikulec, Kathy ^a   Little, David G ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b University of Sydney   (Australia)

Author keywords

Bisphosphonates; Bone; Bone morphogenetic proteins; NF1; Orthopedics; Type 1 neurofibromatosis

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; SODIUM CHLORIDE; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MINERALIZATION; BONE RADIOGRAPHY; CELL CULTURE; CELL ISOLATION; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; GENOTYPE; HETEROTOPIC OSSIFICATION; MALE; MORPHOMETRICS; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUADRICEPS FEMORIS MUSCLE; TREATMENT RESPONSE; WILD TYPE;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; BONE MORPHOGENETIC PROTEINS; CELL SURVIVAL; CELLS, CULTURED; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENERGY METABOLISM; FEMALE; FEMUR; HAPLOTYPES; IMIDAZOLES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; OSTEOBLASTS; SKULL; TIBIA; TRANSFORMING GROWTH FACTOR BETA;

EID: 38049043427     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20481     Document Type: Article

References (39)

1. Young H, Hyman S, North K. 2002. Neurofibromatosis 1: clinical review and exceptions to the rules. J Child Neurol 17:613-621.
2. Friedman JM. 2002. Neurofibromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol 17:548-554.
3. Morrissy RT, Riseborough EJ, Hall JE. 1981. Congenital pseudarthrosis of the tibia. J Bone Joint Surg [Br] 63:367-375.
4. Kuorilehto T, Poyhonen M, Bloigu R, et al. 2005. Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int 16:928-936.
5. Lammert M, Kappler M, Mautner VF, et al. 2005. Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos Int 16:1161-1166.
6. Stevenson DA, Moyer-Mileur LJ, Murray M, et al. 2007. Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr 150:83-88.
7. Gutmann DH, Wood DL, Collins FS. 1991. Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci U S A 88:9658-9662.
8. Kuorilehto T, Ekholm E, Nissinen M, et al. 2006. NF1 gene expression in mouse fracture healing and in experimental rat pseudarthrosis. J Histochem Cytochem 54: 363-370.
9. Bollag G, Clapp DW, Shih S, et al. 1996. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in hematopoietic cells. Nat Genet 12:144-148.
10. McCormick F. 1995. Ras signaling and NF1. Curr Opin Genet Dev 5:51-55.
11. Nakayama K, Tamura Y, Suzawa M. 2003. Receptor tyrosine kinases inhibit bone morphogenetic protein-Smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells. J Bone Miner Res 5:827-835.
12. Schindeler A, Little DG. 2006. Ras-MAPK signaling in osteogenic differentiation: friend or foe? J Bone Miner Res 21:1331-1338.
13. Yu X, Chen S, Potter OL, et al. 2005. Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone 36:793-802.
14. Wu X, Estwick SA, Chen S, et al. 2006. Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem/progenitor cells. Hum Mol Genet 15:2837-2845.
15. Miyazaki T, Katagiri H, Kanegae Y, et al. 2000. Reciprocal role of ERK and NF-κB pathways in survival and activation of osteoclasts. J Cell Biol 148:333-342.
16. Nakamura H, Hirata A, Tsuji T, et al. 2003. Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J Bone Miner Res 18:1198-1205.
17. Yang FC, Chen S, Robling AG, et al. 2006. Hyperactivation of p21 and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 116:2880-2891.
18. Stevenson DA, Zhou H, Ashrafi S, et al. 2006. Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 79:143-148.
19. Johnston CE 2nd. 2002. Congenital pseudarthrosis of the tibia: results of technical variations in the Charnley-Williams procedure. J Bone Joint Surg [Am] 84:1799-1810.
20. Govender S, Csimma C, Genant HK, et al. 2002. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomised study of four hundred and fifty patients. J Bone Joint Surg [Am] 84:2123-2134.
21. Friedlaender GE, Perry CR, Cole JD, et al. 2001. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg [Am] 83 (Suppl 1):151-158.
22. Fabeck L, Ghafil D, Gerroudj M, et al. 2006. Bone morphogenetic protein 7 in the treatment of congenital pseudarthrosis of the tibia. J Bone Joint Surg [Br] 88:116-118.
23. Anticevic D, Jelic M, Vukicevic S. 2006. Treatment of a congenital pseudarthrosis of the tibia by osteogenic protein-1 (bone morphogenetic protein-7): a case report. J Pediatr Orthop B 15:220-221.
24. Lee FY, Sinicropi SM, Lee FS, et al. 2006. Treatment of congenital pseudarthrosis of the tibia with recombinant human bone morphogenetic protein-7 (rhBMP-7). A report of five cases. J Bone Joint Surg [Am] 88:627-633.
25. Little DG, McDonald M, Bransford R, et al. 2005. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res 20:2044-2052.
26. Chen WJ, Jingushi S, Hirata G, et al. 2004. Intramuscular bone induction by the simultaneous administration of recombinant human bone morphogenetic protein 2 and bisphosphonate for autobone graft. Tissue Eng 10:1652-1661.
27. Jeppsson C, Astrand J, Tagil M, et al. 2003. A combination of bisphosphonate and BMP additives in impacted bone allografts. Acta Orthop Scand 74:483-489.
28. Simmons DJ, Kent GN, Jilka RL, et al. 1982. Formation of bone by isolated, cultured osteoblasts in millipore diffusion chambers. Calcif Tissue Int 34:291-294.
29. Volek-Smith H, Urist MR. 1996. Recombinant human bone morphogenetic protein (rhBMP) induced heterotopic bone development in vivo and in vitro. Proc Soc Exp Biol Med 211:265-272.
30. Brannan CI, Perkins AS, Vogel KS, et al. 1994. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 8:1019-1029.
31. Fridman M, Maruta H, Gonez J, et al. 2000. Point mutations of c-Raf RBD with elevated binding to v-Ha-Ras. J Biol Chem 29:30363-30371.
32. Lai CF, Cheng SL. 2002. Signal transductions induced by bone morphogenetic protein-2 and transforming growth factor-beta in normal human osteoblastic cells. J Biol Chem 277:15514-15522.
33. Stoeger T, Proetzel GE, Welzel H, et al. 2002. In situ gene expression analysis during BMP2-induced ectopic bone formation in mice shows simultaneous endochondral and intramembranous ossification. Growth Factors 20:197-210.
34. Yu X, Milas J, Watanabe N, et al. 2006. Neurofibromatosis type 1 gene haploinsufficiency reduces AP-1 gene expression without abrogating the anabolic effect of parathyroid hormone. Calcif Tissue Int 78:162-170.
35. Vahle JL, Sato M, Long GG, et al. 2002. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312-321.
36. Santa-Comba A, Pereira A, Lemos R, et al. 2001. Evaluation of carboxymethylcellulose, hydroxypropylmethylcellulose, and aluminum hydroxide as potential carriers for rhBMP-2. J Biomed Mater Res 55:396-400.
37. Kaneko H, Arakawa T, Mano H, et al. 2000. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 27:479-486.
38. Koide M, Murase Y, Yamato K, et al. 1999. Bone morphogenetic protein-2 enhances osteoclast formation mediated by interleukin-1alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2. Biochem Biophys Res Commun 259:97-102.
39. Woo SB, Hellstein JW, Kalmar JR. 2006. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753-761.